Number needed to harm in the post‐marketing safety evaluation: results for rosiglitazone and pioglitazone

ConclusionThe NNH values suggested an increased CV risk with rosiglitazone versus pioglitazone across several sources of information. The inclusion of objective metrics in post‐marketing drug's benefit–risk assessments could be of increased value and help RAs to make consistent decisions on drug safety. Copyright © 2015 John Wiley & Sons, Ltd.

Source: Pharmacoepidemiology and Drug Safety - September 1, 2015 Category: Drugs & Pharmacology Authors: Diogo Mendes, Carlos Alves, Francisco Batel‐Marques Tags: Original Report Source Type: research